CME CME GROUP INC. Insider Trading

Director Shepard purchases 339 shares of CME at $230.57; stock down -33.6% from 52-week high and -20.1% in 30 days.

William R Shepard, a Director, executed 2 separate purchases totaling 339 shares for $78,186.29 at a blended average price of $230.57 on 2026-06-25, increasing his holdings from 260,103 shares to 260,442 shares. The purchases occurred as CME shares trade at $218.58, down -33.6% from the 52-week high of $329.16 and down -20.1% over the prior 30 days. Shepard's track record across all tickers shows 20 prior buys with an average 90-day return of +2.7% and a 90-day win rate of 70.00%, though his same-ticker history at CME is mixed: 3 of 5 prior buys showed positive 90-day returns. The current purchase occurs in a period of significant recent weakness, following a -26.0% decline over 90 days.

CME Chief HR Officer Harris sold 5,753 shares at $304.63 for $1,752,536.39; holdings reduced to 27,702 shares

Piell Hilda Harris, Sr MD & Chief HR Officer, executed an open-market sale of 5,753 shares at $304.63 on 2026-05-18, reducing her holdings from 33,455 shares to 27,702 shares. Across her cross-ticker open-market history, her 4 prior sells averaged 90-day return of -3.8% with a 90d well-timed rate of 100.00%, though at CME specifically, all 4 prior sells executed on 2024-05-08 posted 90-day returns of -3.8% each. The current share price of $302.37 sits -8.1% from the 52-week high of $329.16, within the 52-week range of $257.17–$329.16. CME's fundamentals show revenue of $1,880,100,000.00 and net income of $1,154,300,000.00 in the latest quarter, with annual revenue growth of +6.4% and a P/E ratio of 4.90.

Terrence A Duffy sells 35,000 CME shares for $10,447,865.76; holds 55,630 post-transaction

Terrence A Duffy, Chairman and CEO of CME Group, executed 2 separate sales totaling 35,000 shares for $10,447,865.76 on 2026-05-15 at blended average price $298.51. This sale reduced his holdings by 38.6% to 55,630 shares remaining. The transaction occurred at prices materially below the current price of $305.12 and well below the 52-week high of $329.16. Across his cross-ticker track record, Duffy's 7 prior sells averaged a 90-day return of +2.4%, indicating his prior sales have generally preceded stock appreciation; at CME specifically, 2 of 5 prior sales posted negative 90-day returns. The stock is trading at a P/E of 4.94 on $1.9B quarterly revenue and $1.2B net income, with annual revenue growth of 6.4%.

Director Shepard buys 1,469 shares at $297.38 for $437.1K; holdings surge 137.4% to 2.5K shares

William R. Shepard, CME Group director, executed 2 separate purchases totaling 1,469 shares for $437,101.02 at a blended average price of $297.38 on 2026-03-26, boosting his post-transaction holdings from 1.1K shares to 2.5K shares (a +137.4% increase). This represents a material accumulation of position. His prior trades at CME show a pattern of well-timed buys: 4 of his last 5 purchases at this ticker posted positive 90-day returns, with his most recent CME buys on 2025-12-30 yielding +6.9% and +4.1% over 90 days. The current purchase occurred when CME is trading at -8.8% from its 52-week high ($326.46), having declined -6.9% in the last 30 days, suggesting accumulation during a pullback. The company's fundamentals remain solid: $1.5B quarterly revenue, $908.0M net income, +6.4% annual revenue growth, and a P/E of 4.82 with $19.8B market cap.

Sr MD General Counsel Marcus Jonathan L sold 3,291 shares ($1.1M) at $333.37 on 2026-03-17; retains 7,192 shares post-transaction.

Senior executive Marcus Jonathan L sold 3,291 shares of CME at $333.37, representing a -31.4% reduction in his CME holdings, while retaining 7,192 shares post-transaction. The transaction occurred at a price $22.66 above the current market price of $310.71, reflecting a sale at a relative premium to recent levels. CME trades at a P/E of 5.03 with $1.5B in quarterly revenue and $908.0M net income, exhibiting solid fundamental performance with 6.4% annual revenue growth. The sale's significance lies in the material reduction of executive exposure to the company, though the substantial retained stake of 7,192 shares indicates continued meaningful ownership alignment.

CME Chief Transformation Officer sells 5,160 shares at $309.00 for $1.6M; reduces stake to 14.9K shares (-25.7%)

Vroman Ken, Chief Transformation Officer at CME GROUP INC., sold 5,160 shares at $309.00 on 2026-03-12, reducing his holdings from 20,070 to 14,910 shares—a 25.7% reduction. The sale occurred at a price $2.19 below the current price of $311.19, and 4.7% below the 52-week high of $326.46. His cross-ticker track record shows an average 90-day return of +6.5% after prior sales, indicating his past open-market sell transactions have been poorly timed (stock subsequently rose). At CME specifically, his single prior sale on 2025-02-13 posted identical return metrics (+3.5% at 30 days, +6.5% at 90 days), with 0 of 1 prior CME sells classified as well-timed. The company fundamentals remain robust—$1.5B latest quarterly revenue, $908.0M net income, and a P/E of 5.04—providing no obvious distress signal. The transaction size and moderate reduction in holdings offer limited insight into executive-level conviction.

Director Bryan T Durkin sold 4,200 CME shares at $309.65; current price $314.00 near 52-week high.

Durkin sold 4,200 shares (8.9% of his pre-transaction holdings) at $309.65 on 2026-02-23, when CME was trading +0.0% from its 52-week high of $314.00. His remaining position is 43,007 shares. At the same ticker, his 1 of 2 prior sells were well-timed at the 90-day mark, though his cross-ticker track record shows an average 90-day return of +4.5% after prior sells, indicating mixed timing outcomes historically. CME's fundamentals remain solid: the company reported revenue of $1,537,600,000.00 in the latest quarter with net income of $908,000,000.00, and the stock has appreciated +11.1% over the past 30 days and +13.4% over 90 days. The sale occurred at a price near recent highs in a rally, but without additional context on scheduling or strategic intent, this represents a routine portfolio transaction.

CME Director William Shepard buys 262 shares in 2 transactions at $278.37 on 2025-12-30

William R. Shepard, Director at CME GROUP INC., made 2 separate purchases totaling 262 shares for $73,008.10 at a blended average price of $278.37 on 2025-12-30, increasing his holdings from 258,447 to 258,709 shares. The purchase occurred near the company's 52-week high of $290.71 (currently -7.2% below peak at $269.68), and comes at a valuation marked by a P/E of 5.04 and annual revenue growth of +9.9% with net income of $908.0M on quarterly revenue of $1,537,600,000.00. Shepard's track record across all tickers shows 20 prior buys with an average 90-day return of +5.3% and a 75.00% win rate; however, at CME specifically, 3 of 5 prior buys were well-timed at the 90-day mark, suggesting selective rather than consistent predictive accuracy at this name. The transaction size represents +0.1% relative to pre-transaction holdings, a modest addition to an already substantial position of 258.4K shares.

CME CEO Terrence A. Duffy sold 25.0K shares for $6.7M on 2025-12-11; holds 65.8K shares remaining (-27.5%)

Terrence A. Duffy, CME's Chairman and CEO, executed two separate sales on 2025-12-11 totaling 25,000 shares (25.0K shares) at blended average $269.55, reducing his holdings by 27.5% from 90.8K to 65.8K shares. The timing is notable: the stock currently trades at $272.18, up 4.8% over 90 days, and his prior four measurable same-ticker sales at CME showed a 75% well-timed rate (three of four resulted in negative 90-day returns, meaning he sold before declines). His cross-ticker track record also demonstrates a 75.00% well-timed rate across five prior sells with an average 90-day return of -2.6%. CME itself remains fundamentally sound with strong recent performance: $1.5B quarterly revenue (+9.9% YoY), $908.0M net income, and an attractive P/E of 5.08. The sale represents a material reduction in the CEO's stake at a price modestly below the 52-week high, warranting close observation of his stated rationale and any subsequent market moves.

CME Group Sr MD sells 7,200 shares for $1,984,798.26 at $275.67 avg, cutting holdings by 50.6%

Sammann Derek, Senior Managing Director of Global Head Commodities Markets at CME Group, executed two separate sales on 2025-11-20 totaling 7,200 shares for $1,984,798.26 at a blended average price of $275.67, reducing his post-transaction holdings from 14,222 shares to 7,022 shares. This represents a substantial reduction of 50.6% of his pre-transaction position. At the current price of $273.09, the executed sales are marginally above current levels, though notably closer to the 52-week high of $290.71 than the low of $225.82. His prior sales at CME (2 measurable outcomes from 2025-05-05) produced flat to slightly positive 90-day returns, with a 0.00% well-timed rate at the 90-day mark across both sales, suggesting this insider's sells at this ticker have not consistently preceded stock declines. CME's fundamentals remain solid with revenue of $1,537,600,000.00, net income of $908,000,000.00, and annual revenue growth of +9.9%, alongside a low P/E of 5.10.